| __timestamp | CRISPR Therapeutics AG | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 241751000 |
| Thursday, January 1, 2015 | 12573000 | 322292000 |
| Friday, January 1, 2016 | 42238000 | 344320000 |
| Sunday, January 1, 2017 | 69800000 | 374644000 |
| Monday, January 1, 2018 | 113773000 | 414604000 |
| Tuesday, January 1, 2019 | 179362000 | 466000000 |
| Wednesday, January 1, 2020 | 266946000 | 535000000 |
| Friday, January 1, 2021 | 438633000 | 643000000 |
| Saturday, January 1, 2022 | 461645000 | 833000000 |
| Sunday, January 1, 2023 | 387332000 | 899625000 |
| Monday, January 1, 2024 | 320653000 |
Unleashing insights
In the rapidly evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Ionis Pharmaceuticals, Inc. and CRISPR Therapeutics AG have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Ionis Pharmaceuticals consistently outspent CRISPR Therapeutics, with R&D expenses peaking at nearly 900 million USD in 2023, a staggering 272% increase from 2014. In contrast, CRISPR Therapeutics, while showing a significant upward trend, reached its highest R&D expenditure of approximately 462 million USD in 2022, marking a 30,000% increase from its modest beginnings in 2014. This data highlights Ionis Pharmaceuticals' aggressive investment strategy, potentially positioning it as a leader in biotech innovation. Meanwhile, CRISPR Therapeutics' exponential growth in R&D spending underscores its emerging role in the industry. As these companies continue to innovate, their R&D investments will likely shape the future of biotechnology.
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Ionis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and Ionis Pharmaceuticals, Inc.
Ascendis Pharma A/S vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Ionis Pharmaceuticals, Inc. or Verona Pharma plc: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
R&D Spending Showdown: Ionis Pharmaceuticals, Inc. vs MorphoSys AG
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Who Prioritizes Innovation? R&D Spending Compared for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and Novavax, Inc.
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Analyzing R&D Budgets: Verona Pharma plc vs CRISPR Therapeutics AG
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Bausch Health Companies Inc.